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Abstract Osteosarcoma is the most common primary
malignant bone tumor. Although cisplatin is the primary
chemotherapy used in osteosarcoma treatment, the cisplatin
resistance remains a big challenge for improving overall
survival. The store-operated calcium (Ca2?) entry (SOCE)
and its major mediator Stim1 have been shown to be
implicated in a number of pathological processes typical
for cancer. In this study, we showed that Stim1 expression
was significantly increased in chemo-resistant osteosar-
coma tissues compared with chemo-sensitivity tissues.
Patients with Sitm1 expression exhibited poorer overall
survival than Stim1-negative patients. Moreover, un-regu-
lation of Stim1 expression and SOCE were also observed
in cisplatin-resistant MG63/CDDP cells compared with
their parental cells. Cisplatin treatment obviously reduced
Stim1 expression and SOCE in cisplatin-sensitivity MG63
cells, but had no effects on MG63/CDDP cells. In addition,
cisplatin resulted in a more pronounced increase of endo-
plasmic reticulum (ER) stress in MG63 cells than in their
resistant variants, which was evidenced by the activation of
molecular markers of ER stress, GRP78, CHOP and ATF4.
Knockdown of Stim1 using siRNA remarkably enhanced
cisplatin-induced apoptosis and ER stress in MG63/CDDP
cells, thereby sensitizing cancer cells to cisplatin. On the
other hand, overexpression of Stim1 markedly reversed
apoptosis and ER stress following cisplatin treatment.
Taken together, these results demonstrate that Stim1 as
well as Ca2? entry contributes cisplatin resistance via
inhibition of ER stress-mediated apoptosis, and provide
important clues to the mechanisms involved in cisplatin
resistance for osteosarcoma treatment. Stim1 represents as
a target of cisplatin and blockade of Stim1-mediated Ca2?
entry may be a useful strategy to improve the efficacy of
cisplatin to treat osteosarcoma.
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Introduction
Osteosarcoma is the most common primary malignant bone
tumor in children and adolescents [1]. It accounts for about
2.4% of all malignancies in pediatric patients and 20% of
primary bone cancer [2]. Patients with osteosarcoma will
receive a three-drug chemotherapy regimen consisting of
cisplatin, doxorubicin and methotrexate, followed by sur-
gical resection of the primary tumor in which higher sur-
vival rates have been achieved [3, 4]. However, the
development of chemo-resistance is a serious problem that
largely limits the efficacy of chemotherapy. While many
efforts have been made in the past [5, 6], little is known
about the molecular mechanisms underlying osteosarcoma
chemo-resistance for clinical therapy.
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Multiple studies have emphasized the critical role of
calcium (Ca2?) and Ca2? ion channel in the regulation of
cancer cell death and apoptosis [7–10]. Store-operated
Ca2? entry (SOCE) has been confirmed as the major Ca2?
influx pathway in non-excitable cells [11, 12]. Stim1,
located in the membrane of endoplasmic reticulum (ER), is
major component of store-operated Ca2? channels and
servers as a sensor of ER Ca2? level [11, 13]. To note,
previous studies have suggested a critical role of Stim1 in
cancerogenesis. Knockdown of Stim1 or pharmacological
inhibition of SOCE suppressed tumor metastasis in animal
models of breast cancer [14]. Moreover, blockade of Stim1
inhibited hepatocarcinoma cell migration and sensitized
prostate cancer cells to therapy [15]. However, the possible
role of Stim1 in osteosarcoma is still inconclusive.
The ER is an essential organelle that is critical for the
biological processes required for cell survival and death
[16]. Upon multiple stimuli, unfolded and incompletely
folded proteins are accumulated in ER, leading to unfolded
protein response and ER stress [16, 17]. Importantly, ER
plays a crucial role in Ca2? homeostasis and Ca2? sig-
naling [18]. Moreover, previous studies have reported that
ER stress can be induced by cisplatin and evidenced by the
activation of molecular markers of ER stress, such as
GRP78, CHOP and ATF4 [19, 20]. Considering the
important role of Stim1 and SOCE in ER stress and
apoptosis [18, 21], we proposed that Stim1 and SOCE
might be involved in cisplatin resistance in cancer cells.
Therefore, in the present study, we explored the corre-
lation between Stim1 and ER stress under cisplatin treat-
ment in osteosarcoma cells, demonstrating that increased
Stim1 as well as Ca2? entry contributes to cisplatin resis-
tance by inhibition of ER stress-mediated apoptosis. Our
findings suggest that targeting Stim1 may be a potential
strategy to improve the efficacy of chemotherapy for
osteosarcoma.
Methods and materials
Patients and specimen preparation
The specimens of tumor tissues were collected from
patients with osteosarcoma who underwent surgical
resection between 2010 and 2013 in the Department of
Orthopedics of The Third Hospital of Hebei Medical
University. These patients were received standardized
protocol consisting of neoadjuvant chemotherapy followed
by appropriate surgical management. The specimens from
60 cases of osteosarcoma were divided into the following
groups based on the follow-up visits from 2011: (1) sub-
jects with a good response and a survival of more than
3 years (n = 28); (2) subjects with a poor response, who
died within 3 years because of requiring chemo-resistance
(n = 32). The chemo-resistance was associated with less
than 25% of tumor shrinkage and 10% of tumor cell
necrotic rate. All tissue specimens were paraffin-embedded
for immunohistochemistry staining, or stored in liquid
nitrogen for western blotting and real-time PCR analysis.
Cell culture
Human osteosarcoma cell line MG63 was obtained from
American Type Culture Collection (ATCC, Rockville,
MD, USA) and cultured in RPMI1640 containing 10%
FBS, 100 U/ml penicillin and 100 lg/ml streptomycin (all
from Invitrogen, Grand Island, NY, USA) in a humidified
atmosphere of 5% CO2 at 37 C. The cisplatin-resistant
MG63 (MG63/CDDP) cells were developed from the par-
ental MG63 cells using an intermittent stepwise selection
protocol as previously described [22, 23].
Immunohistochemistry
Immunohistochemistry was used to detect the expression of
Stim1 in all tissue specimens. The paraffin-embedded
specimens were cut into 8-lm-thick sections, and
deparaffinized and rehydrated in a graded series of alco-
hols. After antigen retrieval, the sections were incubated
with 3% hydrogen peroxide for 10 min to block endoge-
nous peroxidase activity, and then were immunostained
with Stim1 antibody (1:50) (Santa Cruz Biotechnology,
Inc., Paso Robles, CA, USA) at 4 C overnight. After
rinsing with PBS, the sections were incubated with horse-
radish peroxidase-conjugated secondary antibody (Zhong-
shan Jinqiao Co., Beijing, China) for 1 h. 3,3-
diaminobenzidine tetrahydrochloride (DAB, Zhongshan
Jinqiao Co.) was used as the substrate for the final visu-
alization. Counterstaining was carried out with hema-
toxylin. The negative controls were processed in a same
protocol with PBS instead of primary antibody. The sec-
tions were observed under a light microscope (Olympus,
Tokyo, Japan).
RNA extraction and real-time PCR
To quantify mRNA expression of Stim1 in tissue speci-
mens, total RNA was prepared using Trizol reagent (In-
vitrogen) according to the manufacturer’s instruction. The
isolated RNA was reverse transcribed using SuperScript II
RT kit (Invitrogen). Stim1 mRNA expression was deter-
mined by real-time PCR on an ABI Prism 7300 (Applied
Biosystems, Foster City, CA, USA) with SYBR Green Real
Time PCR kit (Invitrogen). b-Actin was used as an internal
control. The following primers were used: Stim1 sense 50-
GAATTGACAAGCCCCTGTGT-30 and antisense 50-
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ATGACTTCCATGCCTTCCAC-30; b-actin sense 50-
GGCGGCACCACCATGTACCCT-30 and antisense 50-
AGGGGCCGGACTCGTCATACT-30.
Western blotting analysis
Tissue specimens or cells were lysed using Western & IP
Cell lysis Kit (Beyotime, Jiangsu, China) supplemented
with protease inhibitor cocktail (Merck, CA, USA). The
protein content was determined by BCA Protein Assay Kit
(Beyotime). 40 lg of protein was separated by 8% SDS-
PAGE and moved to polyvinylidene difluoride (PVDF)
membranes (Millipore, Bedford, MA, USA). Blots were
blocked and probed with antibodies against Stim1 (1:500),
GAPDH (1:1000) (Santa Cruz Biotechnology), GRP78,
CHOP, ATF4 (1:1000, Cell Signaling Technology Inc.,
Beverly, MA, USA) overnight at 4 C. After washing, the
blots were incubated with horseradish peroxidase-conju-
gated secondary antibodies for 1 h at room temperature and
then visualized by ECL detection kit (Beyotime).
Intracellular calcium ([Ca21]i) measurements
[Ca2?]i measurement was performed in 25 mm coverslip
with cells after treatment indicated in the figure legends.
Cells were loaded with 2 lM of Fura 2-AM (Invitrogen) in
2 ml of modified Krebs solution (in mM: 119 NaCl, 2.5
KCl, 1 NaH2PO4, 1.3 MgCl2, 20 HEPES, 11 glucose, 0.5
EGTA, pH 7.4) and incubated for 30 min at 37 C. Ca2?
stores were passively depleted with 1 lM of thapsigargin
(Tg) followed by addition of 1.8 mM of Ca2?. [Ca2?]i was
measured using a wide-field inverted IX81 Olympus
microscope with 340- and 380-nm wavelength filters, and
analyzed with Olympus Cell^R software. A field of about
20 cells was imaged in each experiment, and the averaged
fluorescence was assessed by counting 10 random fields per
group in 6 independent experiments.
Small interfering RNA-mediated gene silencing
of Stim1
Stim1 knockdown in osteosarcoma cells was performed by
transfection of human Stim1 siRNA (Applied Biosystems).
The siRNA sequence targeting Stim1 was 50-GGCTCTG
GATACAGTGCTC-30 (Stim1 siRNA) or 50-GAGCACUG
UAUCCAGAGCCTT-30 (Stim1 siRNA-1). The non-speci-
fic siRNA oligonucleotides (Applied Biosystems) were used
as a negative control. The siRNAs were transfected with
Hiperfect Transfection Reagent (Qiagen, Valencia, CA,
USA) according to the manufacturer’s instructions.
Transfection
Full-length cDNAs for human STIM1 (NM_003156) were
purchased from OpenBioSystems (Huntsville, AL, USA),
and then were subcloned into the expression vector
pSMCV (OpenBioSystems). The plasmid was confirmed
by sequencing. To overexpress Stim1 in osteosarcoma,
cells were transfected transiently with Stim1 plasmid for
24 h using the Lipofectamine Plus reagent (Invitrogen) in
Opti-MEM medium (Invitrogen) according to the sup-
plier’s instructions.
Cell viability assay
MG63 cells or MG63/CDDP cells were seeded in 96-well
plates at a density of 5 9 103 cells/well overnight. After
corresponding treatment indicated in the figure legends,
CCK-8 reagent (Dojindo Laboratories, Kumamoto, Japan)
was added and incubated for another 2 h at 37 C. The
absorbance of each well was measured at 450 nm by a
plate reader (Bio-Tek, Winooski, VT, USA).
Flow cytometry assay
MG63 cells or MG63/CDDP cells were harvested and cell
apoptosis was determined by Annexin V-FITC/PI double-
staining assay (Keygen, Jiangsu China) according to the
manufacturer’s instructions. Apoptotic cells were counted
with FAC-Scan flow cytometer (BD Biosciences, San Jose,
CA, USA) and data were analyzed by CFlow Plus software
(BD Biosciences).
Statistical analysis
The results were presented as mean ± SEM. One-way
analysis of variance (ANOVA) or the unpaired two-tailed
Student’s t test was performed to compare the differences
among groups using SPSS 15.0 statistical software (SPSS
Inc., Chicago, IL, USA). Survival curves were estimated
using Kaplan–Meier method and compared by log rank
test. P value less than 0.05 was considered to indicate a
significant difference.
Results
Increased Stim1 expression in chemo-resistant
osteosarcoma tissues
To determine the role of Stim1 in osteosarcoma, we first
utilized immunohistochemistry to study the expression pat-
terns of Stim1 in chemo-sensitive and resistant osteosarcoma
tissues. The results showed that Stim1 was overexpressed in
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the chemo-resistant subjects who died within 3 years
(Fig. 1a). Consistently, real-time PCR results revealed that
the mRNA expression of Stim1 was also increased in
chemo-resistant osteosarcoma tissues as compared with
chemo-sensitive osteosarcoma tissues (Fig. 1b). Moreover,
the protein expression of Stim1 determined by western
blotting was similar to the immunohistochemistry and real-
time PCR results (Fig. 1c), indicating that the increased
Stim1 expression may be associated the chemo-resistance in
osteosarcoma. Notably, Kaplan–Meier survival analysis
revealed that Stim1-positive patients showed lower overall
survival than those with Stim1-negative expression
(P = 0.02 log-rank test) (Fig. 1d).
Cisplatin decreases Stim1 expression and SOCE
in cisplatin-sensitive osteosarcoma cells
To understand the link between Stim1 expression and cis-
platin resistance in osteosarcoma cells, cisplatin-sensitive and
resistant cells were treated with cisplatin for 24 h. In accord
with the results fromhuman tissue samples, higher expression
of Stim1 was also found in cisplatin-resistant MG63/CDDP
cells than in parent MG63 cells. Additionally, exposure of
MG63 cells to cisplatin significantly decreased Stim1
expression, but had no effect in MG63/CDDP cells (Fig. 2a).
As Stim1 is important for SOCE [12, 13], we next tested
whether SOCE is altered upon cisplatin treatment. In the
absence of extracellular Ca2?, cisplatin significantly inhibited
thapsigargin (Tg)-induced Ca2? release from ER store in
MG63, but had no effect on MG63/CDDP cells. Notably, the
SOCE, which was initiated by addition of external Ca2?
(2 mM), was dramatically increased in cisplatin-resistant
MG63/CDDP cells compared with the parental cells. Fur-
thermore, the Ca2? influx was remarkably decreased by cis-
platin treatment in MG63 cells, but not in cisplatin-resistant
MG63/CDDP cells (Fig. 2b, c). Collectively, these results
suggest that cisplatin inhibits Ca2? release and entry at least
partially via decreasing Stim1 expression.
Cisplatin resistance is associated with inhibition
of ER stress in osteosarcoma cells
Since the shortage of ER Ca2? may causes ER stress and
apoptosis [21], we next evaluated if ER stress is involved in
Fig. 1 Stim1 is highly expressed in chemo-resistant osteosarcoma
tissues. a Paraffin-embedded sections of chemo-sensitive osteosar-
coma and chemo-resistant osteosarcoma tissues were collected.
Expression of Stim1 was detected by immunohistochemistry.
b Real-time PCR analysis to quantify the endogenous expression of
Stim1 in chemo-sensitive tissue (n = 28) compared with chemo-
resistant tissues (n = 32). c Stim1 protein expression was determined
by Western blotting and quantitative results of Stim1 expression were
presented. **P\ 0.01 versus chemo-sensitive tissue. d Correlation of
Stim1 expression and overall survival in patients with osteosarcoma
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cisplatin resistance in osteosarcoma cells. MG63 and
MG63/CDDP cells were treated with cisplatin for 24 h,
respectively. Our results showed that cisplatin significantly
increased the expression of molecular markers of ER stress,
such as GRP78, CHOP and ATF4 in cisplatin-sensitive
MG63 cells. Interestingly, the increase of GRP78, CHOP
and ATF4 expression observed in MG63 cells was at least
three times higher than in their counterparts, although
cisplatin also resulted in a slight increase in these proteins
in cisplatin-resistant MG63/CDDP cells (Fig. 3a–c). Taken
together, these findings demonstrate that cisplatin-induced
ER stress in chemo-sensitive osteosarcoma cells is more
pronounced than in chemo-resistant cells.
Stim1 knockdown sensitizes cisplatin-resistant
osteosarcoma cells to cisplatin via enhancing ER
stress-mediated apoptosis
To elucidate whether Stim1 is involved in cisplatin resis-
tance in osteosarcoma cells, cisplatin-resistant MG63/
CDDP cells were transfected with Stim1 or negative
siRNA for 24 h, followed by cisplatin incubation for 24 h.
Down-regulation of Stim1 in MG63/CDDP was confirmed
by western blotting (Fig. 4a). Expectedly, Tg-induced
Ca2? entry was significantly decreased by Stim1 down-
regulation (Fig. 4b). Moreover, inhibition of Stim1 signif-
icantly enhanced cisplatin-induced the decrease in cell
Fig. 2 Cisplatin resistance is associated with higher expression of
Stim1 in human osteosarcoma cells. a Cisplatin-sensitive (MG63) and
resistant cells (MG63/CDDP) were treated with cisplatin (CDDP, 0 or
10 lM) for 24 h. Stim1 expression was examined by western blotting.
**P\ 0.01 versus MG63 cells, n = 6. b The cells were loaded with
Fura 2-AM probe and subjected to Ca2? imaging experiment.
c Quantification of the thapsigargin (Tg)-induced SOCE amplitude
in MG63 or MG63/CDDP cells treated with or without cisplatin
(10 lM). **P\ 0.01 versus MG63 cells, n = 5
Fig. 3 Cisplatin-induced ER stress in cisplatin-sensitive cells is more
significant than in their resistant counterparts. a–c Cisplatin-sensitive
(MG63) and resistant cells (MG63/CDDP) were treated with cisplatin
(CDDP, 0 or 10 lM) for 24 h. The protein expressions of GRP78 (a),
CHOP (b) and ATF4 (c) were detected by western blotting.
**P\ 0.01 versus MG63 cells; ##P\ 0.01 versus MG63 cells ? cis-
platin; &P\ 0.05 versus MG63/CDDP cells, n = 5
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viability of MG63/CDDP cells (Fig. 4c). Similar results
were observed when we used another siRNA sequence
targeting Stim1, excluding the possibility that the effects of
Stim1 down-regulation on cell viability were associated
with the off-target effect (Figure S1). To test whether the
decreased cell viability results from cell apoptosis,
Annexin V-FITC/PI double staining flow cytometry was
performed. The results showed that blockade of Stim1
markedly increased the percentage of apoptotic cells
induced by cisplatin from 17.08 to 29.57% (Fig. 4d;
Fig. 4 Knockdown of Stim1 increases chemo-sensitivity of cis-
platin-resistant osteosarcoma cells to cisplatin treatment. a Cisplatin-
resistant MG63/CDDP cells were transfected with negative siRNA
(Neg), or different concentrations of Stim1-targeting siRNA (25, 50
and 100 nM) using Hiperfect reagent (Hiper) for 24 h. Stim1
expression was determined by western blotting. **P\ 0.01 versus
control, n = 4. b Quantification of the thapsigargin (Tg)-induced
SOCE amplitude in MG63/CDDP cells transfected with negative or
Stim1 siRNA. **P\ 0.01 versus control, n = 6. c MG63/CDDP
cells were transfected with negative or Stim1 siRNA (50 nM) for
24 h, followed by incubation of cisplatin (10 lM) for another 24 h.
Cell viability was examined by CCK-8 assay. *P\ 0.05 versus
negative; ##P\ 0.01 versus negative ? cisplatin, n = 6. d Cell
apoptosis was determined by Annexin V-FITC/PI staining followed
by flow cytometry. e After treatments mentioned above, the protein
expressions of GRP78, CHOP, ATF4 and Stim1 were examined by
western blotting. f Densitometric analysis of the above protein
expressions. *P\ 0.05, **P\ 0.01 versus negative; ##P\ 0.01
versus negative ? cisplatin; &&P\ 0.01 versus Stim1 siRNA, n = 6
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Figure S2A). In addition, cisplatin-induced the increase of
GRP78, CHOP and ATF4 expressions were more pro-
nounced in Stim1 siRNA-treated cells than in negative
siRNA-treated cells. Of note, although cisplatin treatment
had no effect on Stim1 expression in negative siRNA-
treated MG63/CDDP cells, it further decreased Stim1
expression in cells treated with Stim1 siRNA (Fig. 4e, f).
Collectively, these results suggest that Stim1 knockdown
promotes ER stress-mediated apoptosis in cisplatin-resis-
tant osteosarcoma cells.
Overexpression of Stim1 inhibits cisplatin-induced
apoptosis in osteosarcoma cells
To further confirm whether cisplatin-inhibited Ca2? influx
(due to loss of Stim1 expression) is essential for ER stress-
mediated apoptosis, we overexpressed Stim1 in cisplatin-
sensitive MG63 cells. Up-regulation of Stim1 in MG63
cells was confirmed by western blotting (Fig. 5a). Ca2?
imaging showed that ectopic expression of Sitm1 restored
cisplatin-induced the decrease of Ca2? influx in MG63
cells (Fig. 5b). Furthermore, up-regulation of Stim1 sig-
nificantly attenuated cisplatin-induced the decrease of
MG63 cell viability (Fig. 5c). Similarly, the apoptosis of
MG63 cells induced by cisplatin was also inhibited by
Stim1 overexpression (Fig. 5d; Figure S2B). Finally,
GRP78, CHOP and ATF4 expression that induce ER stress
were all decreased in Stim1 overexpressing cells that were
treated with cisplatin (Fig. 5e, f). Overall, the results
demonstrate that elevated Stim1 expression restores cis-
platin-inhibited Ca2? influx and attenuates ER stress-me-
diated apoptosis in osteosarcoma cells.
Discussion
In the present study, we observed up-regulation of Stim1 in
chemo-resistant osteosarcoma tissues and cisplatin-resis-
tant osteosarcoma cells. In addition, we demonstrated for
the first time that cisplatin decreased Stim1 expression and
SOCE in cisplatin-sensitive osteosarcoma cells, but not in
cisplatin-resistant cells. Blockade of Stim1 and SOCE
promoted ER-stress-mediated apoptosis induced by cis-
platin, which conferred cisplatin resistance in human
osteosarcoma cells. These findings provide important clues
to the mechanisms involved in cisplatin resistance for
osteosarcoma treatment.
Cisplatin is an efficient anti-cancer widely used for the
treatment of various cancers [24]. However, frequent
acquisition of cisplatin-resistant phenotypes is usually
observed in cisplatin treatment, which has become a sig-
nificant obstacle to develop better clinical use of cisplatin
[6, 25]. It is urgent to understand the molecules involved in
cell death and chemo-resistance resulting from cisplatin
therapy. Here, to the best of our knowledge, our findings
were the first to demonstrate that Stim1 expression could
be up-regulated in chemo-resistant osteosarcoma tissues. In
line with these results, we also found that Stim1 expression
and SOCE were both increased in cisplatin-resistant
MG63/CDDP cells compared to cisplatin-sensitive cells.
These results, together with a previous study showing that
Stim1 was overexpressed in liver cancer tissues compared
with non-tumor tissues [15], indicate that Stim1 plays an
important role not only in oncogenesis but also in chemo-
resistance. Importantly, patients with Stim1-positive
expression showed poorer survival than Stim1-negative
patients, implying existence of Stim1 expression predicted
worst survival and may as a critical prognostic indicator for
osteosarcoma survival. Moreover, we found that cisplatin
decreased Stim1 expression and SOCE in MG63 cells, but
not in their resistant variants, further suggesting that
increased Stim1 expression and subsequent SOCE may be
a determinant of cisplatin resistance in osteosarcoma cells.
Intracellular Ca2? serves as a vital role in regulating a
plethora of cellular processes, including neural excitation,
skeletal muscle contraction, endothelial cell proliferation
and macrophage inflammation [7, 10, 11, 26]. Stim1 is the
origin of SOCE, which has been implicated in several
pathological processes of cancer, such as liver and breast
cancer cell migration and metastasis [14, 15]. Previous
studies suggested that Stim1 as well as SOCE contributed
cancer cell apoptosis in response to different chemothera-
peutic drugs. For example, Stim1 down-regulation was
found to promote apoptosis induced by cisplatin in non-
small cell lung cancer cells [8]. Recent study showed that
pharmacological inhibition of SOCE sensitizes hepatocar-
cinoma cells to 5-fluorouracil treatment by increasing
autophagic cell death [9]. Consistent with these results, we
evidenced that knockdown of Stim1 sensitizes human
osteosarcoma cells to cisplatin treatment, whereas over-
expression of Stim1 increased chemo-resistance in cis-
platin-resistant cells.
Since ER stress has been identified as a critical regulator of
sensitivity to chemotherapy [27, 28], we next investigated the
link between Stim1 and ER stress under cisplatin treatment.
Here, our results showed that the increase of GRP78, CHOP,
ATF4 expressions in cisplatin-sensitiveMG63 cells wasmore
pronounced than in the resistant cells in the presence of cis-
platin, indicating the inhibition of ER stress may be required
for cisplatin resistance. Moreover, knockdown of Stim1 fur-
ther enhanced cisplatin-induced the increase of GRP78,
CHOP and ATF4 in cisplatin-resistant MG63 cells, whereas
overexpression of Stim1 was associated with decreased ER
stress in cisplatin-sensitive cells. These results suggest that
cisplatin decreases Stim1 expression and subsequent SOCE, a
vital cell death mechanism for prevention of ER Ca2?
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refilling, which ultimately results in ER stress-mediated
apoptosis. It was worthy to note that induction of GRP78may
trigger pro-survival signaling that promotes resistance of
chemotherapy, since it assists in the folding of nascent
unfolded proteins [29, 30]. However, if the ER stress persists,
the expression ofCHOPandATF4 thatmediate the ER stress-
induced apoptosis can be also induced, which may contribute
to apoptosis overwhelming the pro-survival role of GRP78
[31]. Furthermore, although cisplatin resulted in a slight
increase of molecular markers of ER stress in cisplatin-resis-
tantMG63cells, it did not have effect onStim1expression and
SOCE, suggesting cisplatin-induced ER stress may be a
multifactorial phenomenon.This shouldbe further explored in
the future.
Fig. 5 Overexpression of Stim1 decreases sensitivity of osteosar-
coma cells to cisplatin treatment. a MG63 were transfected with
Stim1 plasmid using Lipofectamine Plus reagent (Lipo) for 24 h.
Stim1 expression was examined by western blotting. **P\ 0.01
versus control, n = 4. b Quantification of the thapsigargin (Tg)-
induced SOCE amplitude in MG63 cells transfected with Stim1
plasmid in the presence of cisplatin (10 lM). **P\ 0.01 versus
control; #P\ 0.05, ##P\ 0.01 versus cisplatin alone, n = 6. c MG63
cells were transfected with Stim1 plasmid for 24 h and then were
incubated with cisplatin for another 24 h. Cell viability was
determined using CCK-8 assay. **P\ 0.01 versus Lipo;
##P\ 0.01 versus Lipo ? cisplatin, n = 6. d Cell apoptosis was
analyzed by Annexin V-FITC/PI staining followed by flow cytometry.
e After treatments mentioned in c, the protein expressions of GRP78,
CHOP, ATF4 and Stim1 were determined by western blotting.
f Densitometric analysis of the above protein expressions. **P\ 0.01
versus Lipo; ##P\ 0.01 versus Lipo ? cisplatin; &&P\ 0.01 versus
Stim1, n = 6
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In summary, we demonstrate that Stim1-mediated
SOCE protects osteosarcoma cells from undergoing apop-
tosis in response to cisplatin. Knockdown of Stim1 effec-
tively sensitizes cells to cisplatin via promoting ER stress-
mediated apoptosis. Our study suggests that targeting
Stim1 may be a therapeutic strategy for osteosarcoma
chemotherapy.
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